{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:04:48Z","timestamp":1790039088217,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015581","name":"Houston Methodist Academic Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015190","name":"Houston Methodist Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajpc.2026.101733","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:41:36Z","timestamp":1784043696000},"page":"101733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral center"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7153-3790","authenticated-orcid":false,"given":"Eleonora","family":"Avenatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sadhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Gullapelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Pavuluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta R.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajpc.2026.101733_bib0001","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/dom.15500","article-title":"Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents","volume":"26","author":"Kunutsor","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1 Suppl 1","key":"10.1016\/j.ajpc.2026.101733_bib0002","first-page":"S181","article-title":"American diabetes association professional practice committee. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"39","key":"10.1016\/j.ajpc.2026.101733_bib0003","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101733_bib0004","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the american college of cardiology solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101733_bib0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/amiajnl-2011-000439","article-title":"Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study","volume":"19","author":"Kho","year":"2012","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101733_bib0006","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the department of veterans affairs","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101733_bib0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00125-024-06321-2","article-title":"Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013-2019","volume":"68","author":"Wang","year":"2025","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101733_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101733_bib0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ajpc.2026.101733_bib0010","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ajpc.2026.101733_bib0011","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101733_bib0012","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101733_bib0013","doi-asserted-by":"crossref","first-page":"e1909","DOI":"10.1210\/clinem\/dgaa938","article-title":"Casting a health equity lens on endocrinology and diabetes","volume":"106","author":"Golden","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101733_bib0014","doi-asserted-by":"crossref","first-page":"e2852","DOI":"10.1210\/clinem\/dgaf301","article-title":"Overcoming disparities in using SGLT2 inhibitors for cardiorenal protection in persons with and without type 2 diabetes","volume":"110","author":"Jack","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:19:00Z","timestamp":1790036340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726003089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":14,"alternative-id":["S2666667726003089"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101733","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral center","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101733"}}